Immunoglobulin therapy

Immunoglobulin therapy
Clinical data
Trade namesFlebogamma, Gammagard, Hizentra, others
Other namesnormal human immunoglobulin (HNIG), human normal immunoglobulin (HNIG)
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: Exempt
Routes of
administration		Intravenous, intramuscular, subcutaneous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • CA: ℞-only
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
ChemSpider
  • none
UNII

Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, capillary leak syndrome and certain other infections when a more specific immunoglobulin is not available. Depending on the formulation it can be given by injection into muscle, a vein, or under the skin. The effects last a few weeks.

Common side effects include pain at the site of injection, muscle pain, and allergic reactions. Other severe side effects include kidney problems, anaphylaxis, blood clots, and red blood cell breakdown. Use is not recommended in people with some types of IgA deficiency. Use appears to be relatively safe during pregnancy. Human immunoglobulin is made from human blood plasma. It contains antibodies against many viruses.

Human immunoglobulin therapy first occurred in the 1930s and a formulation for injection into a vein was approved for medical use in the United States in 1981. It is on the World Health Organization's List of Essential Medicines. Each formulation of the product is somewhat different. A number of specific immunoglobulin formulations are also available including for hepatitis B, rabies, tetanus, varicella infection, and Rh positive blood exposure.

Medical uses

Immunoglobulin therapy is used in a variety of conditions, many of which involve decreased or abolished antibody production capabilities, which range from a complete absence of multiple types of antibodies, to IgG subclass deficiencies (usually involving IgG2 or IgG3), to other disorders in which antibodies are within a normal quantitative range, but lacking in quality – unable to respond to antigens as they normally should – resulting in an increased rate or increased severity of infections. In these situations, immunoglobulin infusions confer passive resistance to infection on their recipients by increasing the quantity/quality of IgG they possess. Immunoglobulin therapy is also used for a number of other conditions, including in many autoimmune disorders such as dermatomyositis in an attempt to decrease the severity of symptoms. Immunoglobulin therapy is also used in some treatment protocols for secondary immunodeficiencies such as human immunodeficiency virus (HIV), some autoimmune disorders (such as immune thrombocytopenia and Kawasaki disease), some neurological diseases (multifocal motor neuropathy, stiff person syndrome, multiple sclerosis and myasthenia gravis) some acute infections and some complications of organ transplantation.

Immunoglobulin therapy is especially useful in some acute infection cases such as pediatric HIV infection and is also considered the standard of treatment for some autoimmune disorders such as Guillain–Barré syndrome. The high demand which coupled with the difficulty of producing immunoglobulin in large quantities has resulted in increasing global shortages, usage limitations and rationing of immunoglobulin.

Australia

The Australian Red Cross Blood Service developed their own guidelines for the appropriate use of immunoglobulin therapy in 1997. Immunoglobulin is funded under the National Blood Supply and indications are classified as either an established or emerging therapeutic role or conditions for which immunoglobulin use is in exceptional circumstances only.

Subcutaneous immunoglobulin access programs have been developed to facilitate hospital based programs.

Human normal immunoglobulin (human immunoglobulin G) (Cutaquig) was approved for medical use in Australia in May 2021.

Canada

The National Advisory Committee on Blood and Blood Products of Canada (NAC) and Canadian Blood Services have also developed their own separate set of guidelines for the appropriate use of immunoglobulin therapy, which strongly support the use of immunoglobulin therapy in primary immunodeficiencies and some complications of HIV, while remaining silent on the issues of sepsis, multiple sclerosis, and chronic fatigue syndrome.

European Union

Brands include HyQvia (human normal immunoglobulin), Privigen (human normal immunoglobulin (IVIg)), Hizentra (human normal immunoglobulin (SCIg)), Kiovig (human normal immunoglobulin), and Flebogamma DIF (human normal immunoglobulin).

In the European Union, human normal immunoglobulin (SCIg) (Hizentra) is used in people whose blood does not contain enough antibodies (proteins that help the body to fight infections and other diseases), also known as immunoglobulins. It is used to treat the following conditions:

It is indicated for replacement therapy in adults and children in primary immunodeficiency syndromes such as:

Flebogamma DIF is indicated for the replacement therapy in adults, children and adolescents (0–18 years) in:

and for the immunomodulation in adults, children and adolescents (0–18 years) in:

In February 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Deqsiga, intended for replacement therapy in people with primary or secondary immunodeficiencies and immunomodulation in people with certain autoimmune diseases. The applicant for this medicinal product is Takeda Manufacturing Austria AG. Deqsiga is a duplicate of Kiovig (human normal immunoglobulin), which was authorized in the EU in January 2006. Deqsiga and Kiovig have the same pharmaceutical form, active substance and indications, but Deqsiga contains lower levels of immunoglobulin A (IgA) and may therefore be more suitable for people with IgA deficiency who have a higher risk of hypersensitivity to immunoglobulin products that contain higher levels of IgA. Deqsiga was authorized for medical use in the European Union in May 2025.

United Kingdom

England's National Health Service recommends the routine use of immunoglobulin for a variety of conditions including primary immunodeficiencies and a number of other conditions, but recommends against the use of immunoglobulin in sepsis (unless a specific toxin has been identified), multiple sclerosis, neonatal sepsis, and pediatric HIV/AIDS.

United States

The American Academy of Allergy, Asthma, and Immunology supports the use of immunoglobulin for primary immunodeficiencies, while noting that such usage actually accounts for a minority of usage and acknowledging that immunoglobulin supplementation can be appropriately used for a number of other conditions, including neonatal sepsis (citing a sixfold decrease in mortality), considered in cases of HIV (including pediatric HIV), considered as a second line treatment in relapsing-remitting multiple sclerosis, but recommending against its use in such conditions as chronic fatigue syndrome, PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection) until further evidence to support its use is found (though noting that it may be useful in PANDAS patients with an autoimmune component), cystic fibrosis, and a number of other conditions.

Brands include:

Side effects

Although immunoglobulin is frequently used for long periods of time and is generally considered safe, immunoglobulin therapy can have severe adverse effects, both localized and systemic. Patients who are receiving immunoglobulin and experience adverse events are sometimes recommended to take acetaminophen and diphenhydramine before their infusions to reduce the rate of adverse effects. Additional premedication may be required in some instances (especially when first getting accustomed to a new dosage), prednisone or another oral steroid. The rate of adverse reactions depends on the route of administration. The traditional intravenous immunoglobulin (IVIG) route is more likely to cause side effects, and to affect a larger part of the body, than the new subcutaneous immunoglobulin (SCIG) route.

Local side effects of immunoglobulin infusions most frequently include an injection site reaction (reddening of the skin around the injection site), itching, rash, and hives. Less serious systemic side effects to immunoglobulin infusions include an increased heart rate, hyper or hypotension, an increased body temperature, diarrhea, nausea, abdominal pain, vomiting, arthralgia or myalgia, dizziness, headache, fatigue, fever, and pain.

Serious side effects of immunoglobulin infusions in infants, children, and adults include chest discomfort or pain, myocardial infarction, tachycardia, hyponatremia, hemolysis, hemolytic anemia, thrombosis, hepatitis, anaphylaxis, backache, aseptic meningitis, acute kidney injury, hypokalemic nephropathy, pulmonary embolism, and transfusion related acute lung injury. There is also a small chance that even given the precautions taken in preparing immunoglobulin preparations, an immunoglobulin infusion may pass a virus to its recipient. Some immunoglobulin solutions also contain isohemagglutinins, which in rare circumstances can cause hemolysis by the isohemagglutinins triggering phagocytosis.

IVIG has long been known to induce a decrease in peripheral blood neutrophil count, or neutropenia in neonates, and in patients with Idiopathic Thrombocytopenic Purpura, resolving spontaneously and without complications within 48 h. Possible pathomechanisms include apoptosis/cell death due to antineutrophil antibodies with or without neutrophil migration into a storage pool outside the blood circulation.

Immunoglobulin therapy interferes with the ability of the body to produce a normal immune response to an attenuated live-virus vaccine (like MMR) for up to a year, can result in falsely elevated blood glucose levels, and can interfere with many of the IgG-based assays often used to diagnose a patient with a particular infection.

As with all blood products, IG carriers a theoretical risk of the transmission of blood-borne diseases. This used to be an issue, but no cases are known since the 21th century with improved screening and control. The process to separate IG from the rest of the blood serum also helps remove pathogens.

Routes of administration

1950s – intramuscular

After immunoglobulin therapy's discovery in 1952, weekly intramuscular injections of immunoglobulin (IMIg) were the norm until intravenous formulations (IVIg) began to be introduced in the 1980s. During the mid and late 1950s,[vague] one-time IMIg injections were a common public health response to outbreaks of polio before the widespread availability of vaccines. Intramuscular injections were extremely poorly tolerated due to their extreme pain and poor efficacy – rarely could intramuscular injections alone raise plasma immunoglobulin levels enough to make a clinically meaningful difference.

1980s – intravenous

Intravenous formulations began to be approved in the 1980s, which represented a significant improvement over intramuscular injections, as they allowed for a sufficient amount of immunoglobulin to be injected to reach clinical efficacy, although they still had a fairly high rate of adverse effects (though the addition of stabilizing agents reduced this further). IVIG causes a peak in Ig levels at about 15 minutes after injection, followed by a steep decline in the first two days and a slower decrease then. In maintenance therapy, it may be used monthly at a high concentration.

1990s – subcutaneous

The first description of a subcutaneous route of administration for immunoglobulin therapy dates back to 1980, but for many years subcutaneous administration was considered to be a secondary choice, only to be considered when peripheral venous access was no longer possible or tolerable.

During the late 1980s and early 1990s,[vague] it became obvious that for at least a subset of patients the systemic adverse events associated with intravenous therapy were still not easily tolerable, and more doctors began to experiment with subcutaneous immunoglobulin administration, culminating in an ad hoc clinical trial in Sweden of 3000 subcutaneous injections administered to 25 adults (most of whom had previously experienced systemic adverse effects with IMIg or IVIg), where no infusion in the ad hoc trial resulted in a severe systemic adverse reaction, and most subcutaneous injections were able to be administered in non-hospital settings, allowing for considerably more freedom for the people involved.

In the later 1990s,[vague] large-scale trials began in Europe to test the feasibility of subcutaneous immunoglobulin administration, although it was not until 2006 that the first subcutaneous-specific preparation of immunoglobulin was approved by a major regulatory agency (Vivaglobin, which was voluntarily discontinued in 2011). A number of other brand names of subcutaneous immunoglobulin have since been approved, although some small-scale studies have indicated that a particular cohort of patients with common variable immunodeficiency (CVID) may develop intolerable side effects with subcutaneous immunoglobulin (SCIg) that they do not with intravenous immunoglobulin (IVIg).

Although intravenous was the preferred route for immunoglobulin therapy for many years, in 2006, the US Food and Drug Administration (FDA) approved the first preparation of immunoglobulin that was designed exclusively for subcutaneous use.

Compared to IVIG, SCIG alows the drug to be released slowly over time from an area beneth the skin. Standard SCIG does not allow a lot of the drug to be stored under the skin, so dosing may be done daily, weekly, or biweekly. An issue with SCIG is that it takes a long time for the pump to inject the medicine. It is now known that the manual "rapid push" process produces similar results medically, so it can be used if the patient wishes to (commonly used in pediatrics). To allow more IG to be absorbed and stored under the skin, the hyaluronidase-facilitated SCIG (fSCIG) uses an enzyme to temporarily break down the hyaluronan around the injection site. It can be used once monthly.

Mechanism of action

The precise mechanism by which immunoglobulin therapy suppresses harmful inflammation is likely multifactorial. For example, it has been reported that immunoglobulin therapy can block Fas-mediated cell death.

Perhaps a more popular theory is that the immunosuppressive effects of immunoglobulin therapy are mediated through IgG's Fc glycosylation. By binding to receptors on antigen presenting cells, IVIG can increase the expression of the inhibitory Fc receptor, FcgRIIB, and shorten the half-life of auto-reactive antibodies. The ability of immunoglobulin therapy to suppress pathogenic immune responses by this mechanism is dependent on the presence of a sialylated glycan at position CH2-84.4 of IgG. Specifically, de-sialylated preparations of immunoglobulin lose their therapeutic activity and the anti-inflammatory effects of IVIG can be recapitulated by administration of recombinant sialylated IgG1 Fc.

Sialylated-Fc-dependent mechanism was not reproduced in other experimental models suggesting that this mechanism is functional under a particular disease or experimental settings. On the other hand, several other mechanisms of action and the actual primary targets of immunoglobulin therapy have been reported. In particular, F(ab')2-dependent action of immunoglobulin to inhibit activation of human dendritic cells, induction of autophagy, induction of COX-2-dependent PGE-2 in human dendritic cells leading to expansion of regulatory T cells, inhibition of pathogenic Th17 responses, and induction of human basophil activation and IL-4 induction via anti-IgE autoantibodies. Some believe that immunoglobulin therapy may work via a multi-step model where the injected immunoglobulin first forms a type of immune complex in the patient. Once these immune complexes are formed, they can interact with Fc receptors on dendritic cells, which then mediate anti-inflammatory effects helping to reduce the severity of the autoimmune disease or inflammatory state.

Other proposed mechanisms include the possibility that donor antibodies may bind directly with the abnormal host antibodies, stimulating their removal; the possibility that IgG stimulates the host's complement system, leading to enhanced removal of all antibodies, including the harmful ones; and the ability of immunoglobulin to block the antibody receptors on immune cells (macrophages), leading to decreased damage by these cells, or regulation of macrophage phagocytosis. Indeed, it is becoming more clear that immunoglobulin can bind to a number of membrane receptors on T cells, B cells, and monocytes that are pertinent to autoreactivity and induction of tolerance to self.

A report stated that immunoglobulin application to activated T cells leads to their decreased ability to engage microglia. As a result of immunoglobulin treatment of T cells, the findings showed reduced levels of tumor necrosis factor-alpha and interleukin-10 in T cell-microglia co-culture. The results add to the understanding of how immunoglobulin may affect inflammation of the central nervous system in autoimmune inflammatory diseases.

Hyperimmune globulin

Hyperimmune globulins or specific IGs are a class of immunoglobulins prepared in a similar way as for normal human immunoglobulin, except that the donor has high titers of antibody against a specific organism or antigen in their plasma (typically from disease recovery or repeated immunization). Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides temporary passive immunity to the patient against an agent. This is in contrast to vaccines that provide active immunity. However, vaccines take much longer to starting working. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.[citation needed]

The first hyper-antisera containing hyper-Igs to see widespread use were the antitoxins, back then produced by immunizing horses against specific toxins. Horses have a lot of blood and produce large amounts of Igs in a short window of time after immunization, making them ideal for the job. The horse-derived sera and globulins are considered heterologous to humans as they contain horse-specific parts. They tend to cause an anti-horse-Ig immunity in humans in the form of serum sickness; sometimes they also cause anaphylaxis. Today horse hyperimmune Igs derived from horse hyperimmune sera are still used to treat snakebite because of how fast they start producing the Igs. A process called "despeciation" removes the horse-specific Fc portion, creating globulins that are less likely to trigger an immune reaction in other animals.

In developed countries, human hyper-Igs have largely replaced horse hyper-Igs in the more common types of antitoxins such as anti-tetanus. There are also many new targets that have ever been available as human versions, such as the Rho(D) immune globulin used to prevent an Rh(D)-negative mother from developing an immune response to here Rh(D)-positive baby. Most people who donate hyper-immune Ig sign up to a program that has them become repeatedly immunized. For newer disease outbreaks for there is no treatment, the hyper-Ig may be taken directly from someone who has recently recovered, such as in a small but successful trial against the Ebola virus in 1999.

Hyperimmune plasma is used in veterinary medicine, with the very same considerations around possible side reactions from heterologous sources.

Society and culture

Economics

In the United Kingdom a dose cost the NHS between £11.20 and £1,200.00 depending on the type and amount.

Brand names

As biologicals, various brand names of immunoglobulin products are not necessarily interchangeable, and care must be exercised when changing between them. Brand names of intravenous immunoglobulin formulations include Flebogamma, Gamunex, Privigen, Octagam, and Gammagard, while brand names of subcutaneous formulations include Cutaquig, Cuvitru, HyQvia, Hizentra, Gamunex-C, and Gammaked.

Supply issues

The United States is one of a handful of countries that allow plasma donors to be paid, meaning that the US supplies much of the plasma-derived medicinal products (including immunoglobulin) used across the world, including more than 50% of the European Union's supply. The Council of Europe has officially endorsed the idea of not paying for plasma donations for both ethical reasons and reasons of safety, but studies have found that relying on entirely voluntary plasma donation leads to shortages of immunoglobulin and forces member countries to import immunoglobulin from countries that do compensate donors.

In Australia, blood donation is voluntary and therefore to cope with increasing demand and to reduce the shortages of locally produced immunoglobulin, several programs have been undertaken including adopting plasma for first time blood donors, better processes for donation, plasma donor centres and encouraging current blood donors to consider plasma only donation.

Research

Experimental results from a small clinical trial in humans suggested protection against the progression of Alzheimer's disease, but no such benefit was found in a subsequent phase III clinical trial. In May 2020, the US approved a phase three clinical trial on the efficacy and safety of high-concentration intravenous immune globulin therapy in severe COVID-19. Efficacy of heterologous immunoglobulin derivatives has been demonstrated in clinical trials of antivenoms for scorpion sting and for snakebite.

References

  1. 1 2 "Xembify APMDS". Therapeutic Goods Administration (TGA). 15 July 2022. Archived from the original on 14 July 2022. Retrieved 17 July 2022.
  2. ↑ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
  3. ↑ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
  4. ↑ "Regulatory Decision Summary - Xembify". Health Canada. 23 October 2014. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
  5. ↑ "Summary Basis of Decision - HyQvia". Health Canada. 23 October 2014. Archived from the original on 5 August 2024. Retrieved 6 August 2022.
  6. ↑ "Immune system health". Health Canada. 9 May 2018. Archived from the original on 19 January 2022. Retrieved 13 April 2024.
  7. ↑ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Archived from the original on 17 April 2024. Retrieved 17 April 2024.
  8. 1 2 "Alyglo- human immunoglobulin g liquid". DailyMed. 15 December 2023. Archived from the original on 3 March 2024. Retrieved 3 March 2024.
  9. 1 2 "Anthrasil (anthrax immune globulin- human liquid". DailyMed. 31 May 2018. Retrieved 7 March 2025.
  10. 1 2 "Asceniv – human immunoglobulin g liquid". DailyMed. Archived from the original on 9 June 2021. Retrieved 9 June 2021.
  11. 1 2 "Bivigam (immune globulin intravenous – human 10% liquid". DailyMed. Archived from the original on 9 June 2021. Retrieved 9 June 2021.
  12. 1 2 "Gammagard Liquid (immune globulin infusion- human injection, solution". DailyMed. 13 November 2024. Retrieved 7 July 2025.
  13. 1 2 "Gammagard S/D (immune globulin intravenous- human kit". DailyMed. 11 March 2025. Retrieved 7 July 2025.
  14. 1 2 "Gamunex-C (immune globulin – human injection". DailyMed. Archived from the original on 9 June 2021. Retrieved 9 June 2021.
  15. 1 2 "Hizentra – human immunoglobulin g liquid". DailyMed. Archived from the original on 9 June 2021. Retrieved 9 June 2021.
  16. 1 2 "Hyqvia (immune globulin 10 percent – human with recombinant human hyaluronidase kit". DailyMed. Archived from the original on 5 August 2020. Retrieved 9 June 2021.
  17. 1 2 "Octagam immune globulin (human)- immune globulin solution". DailyMed. 26 January 2024. Archived from the original on 26 February 2024. Retrieved 26 February 2024.
  18. 1 2 "Panzyga (immune globulin intravenous – human solution". DailyMed. Archived from the original on 9 June 2021. Retrieved 9 June 2021.
  19. 1 2 "Xembify – immune globulin subcutaneous, human-klhw solution". DailyMed. Archived from the original on 9 June 2021. Retrieved 9 June 2021.
  20. 1 2 "HyQvia EPAR". European Medicines Agency (EMA). 3 June 2013. Archived from the original on 15 July 2020. Retrieved 14 July 2020.
  21. 1 2 "Privigen EPAR". European Medicines Agency (EMA). 20 May 2008. Archived from the original on 15 July 2020. Retrieved 14 July 2020.
  22. 1 2 3 4 5 6 7 8 9 10 11 12 13 "Hizentra EPAR". European Medicines Agency (EMA). 6 June 2011. Archived from the original on 1 August 2020. Retrieved 2 May 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  23. 1 2 "Kiovig EPAR". European Medicines Agency (EMA). 13 June 2008. Archived from the original on 17 July 2020. Retrieved 14 July 2020.
  24. 1 2 3 4 5 6 7 8 9 10 "Flebogamma DIF EPAR". European Medicines Agency (EMA). 18 August 2009. Archived from the original on 15 July 2020. Retrieved 15 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  25. 1 2 3 4 5 6 "Deqsiga EPAR". European Medicines Agency (EMA). 27 February 2025. Retrieved 6 March 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  26. 1 2 "Deqsiga PI". Union Register of medicinal products. 5 May 2025. Retrieved 14 June 2025.
  27. 1 2 3 4 5 6 7 8 "Immune Globulin". The American Society of Health-System Pharmacists. Archived from the original on 9 January 2017. Retrieved 8 January 2017.
  28. 1 2 3 4 5 6 British national formulary: BNF 69 (69 ed.). British Medical Association. 2015. pp. 867–871. ISBN 978-0-85711-156-2.
  29. ↑ Etzioni A, Ochs HD (2014). Primary Immunodeficiency Disorders: A Historic and Scientific Perspective. Academic Press. pp. 283–284. ISBN 978-0-12-411554-5. Archived from the original on 9 January 2017.
  30. ↑ Organization WH (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  31. ↑ Organization WH (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  32. 1 2 Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. (April 2006). "Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology". The Journal of Allergy and Clinical Immunology (Review). 117 (4 Suppl): S525–S553. doi:10.1016/j.jaci.2006.01.015. PMID 16580469.
  33. ↑ van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC (May 2010). "IVIG treatment and prognosis in Guillain-Barré syndrome". Journal of Clinical Immunology. 30 (S1): S74–S78. doi:10.1007/s10875-010-9407-4. PMC 2883091. PMID 20396937.
  34. ↑ Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, et al. (September 2003). "Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology". Neurology. 61 (6): 736–740. doi:10.1212/WNL.61.6.736. PMID 14504313. S2CID 20577426.
  35. ↑ Pondrom S (October 2014). "The IVIg dilemma". The AJT Report. American Journal of Transplantation. 14 (10): 2195–2196. doi:10.1111/ajt.12995. PMID 25231064. S2CID 221433035.
  36. ↑ "Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia | National Blood Authority". www.blood.gov.au. Archived from the original on 1 March 2020. Retrieved 14 November 2019.
  37. ↑ "Access to Intravenous Immunoglobulin (IVIg)". National Blood Authority. Archived from the original on 2 April 2020. Retrieved 14 November 2019.
  38. ↑ "Access to Subcutaneous Immunoglobulin (SCIg)". National Blood Authority. Archived from the original on 1 March 2020. Retrieved 14 November 2019.
  39. ↑ "Cutaquig". Therapeutic Goods Administration (TGA). 12 May 2021. Archived from the original on 6 September 2021. Retrieved 6 September 2021.
  40. ↑ Anderson D, Ali K, Blanchette V, Brouwers M, Couban S, Radmoor P, et al. (April 2007). "Guidelines on the use of intravenous immune globulin for hematologic conditions". Transfusion Medicine Reviews. 21 (2 Suppl 1): S9–56. doi:10.1016/j.tmrv.2007.01.001. PMID 17397769.
  41. ↑ "Clinical Commissioning Policy for the use of therapeutic immunoglobulin" (PDF). National Health Service England. Retrieved 12 July 2026.{{cite web}}: CS1 maint: url-status (link)
  42. ↑ "Eight guiding principals for safe, effective and appropriate use of IVIG" (PDF). American Association of Allergists and Immunologists. Archived (PDF) from the original on 5 March 2016. Retrieved 5 December 2015.
  43. ↑ Center for Biologics Evaluation and Research (15 December 2023). "Alyglo". U.S. Food and Drug Administration (FDA). FDA. Archived from the original on 22 December 2023. Retrieved 22 December 2023.
  44. ↑ Center for Biologics Evaluation and Research (1 October 2024). "Anthrasil". U.S. Food and Drug Administration (FDA). FDA. Retrieved 7 March 2025.
  45. ↑ Center for Biologics Evaluation and Research (1 March 2024). "Asceniv". U.S. Food and Drug Administration (FDA). FDA. Archived from the original on 13 June 2024. Retrieved 5 August 2024.
  46. ↑ Center for Biologics Evaluation and Research (1 March 2024). "Bivigam". U.S. Food and Drug Administration (FDA). FDA. Archived from the original on 5 August 2024. Retrieved 5 August 2024.
  47. ↑ Center for Biologics Evaluation and Research (27 June 2025). "Gammagard Liquid". U.S. Food and Drug Administration (FDA). FDA. Archived from the original on 21 May 2025. Retrieved 7 July 2025.
  48. ↑ "Takeda Announces U.S. FDA Approval of Gammagard Liquid ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content" (Press release). Takeda. 30 June 2025. Retrieved 7 July 2025 – via Business Wire.
  49. ↑ "GAMMAGARD LIQUID ERC Prescribing Information". Archived from the original on 30 June 2025. Retrieved 7 July 2025.
  50. ↑ Center for Biologics Evaluation and Research (28 March 2018). "Gammagard S/D". U.S. Food and Drug Administration (FDA). FDA. Archived from the original on 30 April 2025. Retrieved 7 July 2025.
  51. ↑ Center for Biologics Evaluation and Research (8 March 2023). "Gamunex-C". U.S. Food and Drug Administration (FDA). FDA. Archived from the original on 5 August 2024. Retrieved 5 August 2024.
  52. 1 2 Center for Biologics Evaluation and Research (21 April 2022). "Hizentra". U.S. Food and Drug Administration (FDA). FDA. Archived from the original on 1 April 2020. Retrieved 5 August 2024.
  53. ↑ "Hyqvia (immune globulin infusion 10%- human with recombinant human hyaluronidase kit". DailyMed. 17 December 2024. Retrieved 7 March 2025.
  54. ↑ Center for Biologics Evaluation and Research (12 January 2024). "Hyqvia". U.S. Food and Drug Administration (FDA). FDA. Archived from the original on 19 May 2024. Retrieved 5 August 2024.
  55. ↑ "Octagam immune globulin (human)- immune globulin solution". DailyMed. 29 January 2024. Retrieved 7 March 2025.
  56. ↑ Center for Biologics Evaluation and Research (10 August 2022). "Octagam". U.S. Food and Drug Administration (FDA). FDA. Archived from the original on 31 May 2024. Retrieved 5 August 2024.
  57. ↑ Center for Biologics Evaluation and Research (11 February 2021). "Panzyga". U.S. Food and Drug Administration (FDA). FDA. Archived from the original on 17 April 2024. Retrieved 5 August 2024.
  58. ↑ Center for Biologics Evaluation and Research (26 September 2025). "Qivigy". U.S. Food and Drug Administration. FDA. Retrieved 3 October 2025.
  59. ↑ Biopharma K (29 September 2025). "Kedrion Biopharma Receives FDA Approval for Qivigy (Immune Globulin 10% IV) for treatment of Primary Humoral Immunodeficiency in Adults and confirms its plan to increase investments in the U.S. throughout its global operations". Kedrion Biopharma. Retrieved 3 October 2025 – via PR Newswire.
  60. ↑ Center for Biologics Evaluation and Research (18 July 2024). "Xembify". U.S. Food and Drug Administration (FDA). FDA. Archived from the original on 10 June 2024. Retrieved 5 August 2024.
  61. ↑ Center for Biologics Evaluation and Research (13 June 2024). "Yimmugo". U.S. Food and Drug Administration (FDA). FDA. Archived from the original on 19 June 2024. Retrieved 5 August 2024.
  62. 1 2 3 Guo Y, Tian X, Wang X, Xiao Z (2018). "Adverse Effects of Immunoglobulin Therapy". Frontiers in Immunology. 9 1299. doi:10.3389/fimmu.2018.01299. PMC 6008653. PMID 29951056.
  63. 1 2 3 4 5 6 "Immune Globulin". Dynamed. Archived from the original on 8 December 2015. Retrieved 23 November 2015.(Subscription may be required or content may be available in libraries.)
  64. ↑ "Comparing Two Treatments for IVIG-Resistant Kawasaki Disease - Evidence Update for Clinicians | PCORI". Comparing Two Treatments for IVIG-Resistant Kawasaki Disease - Evidence Update for Clinicians | PCORI. 9 May 2024. Archived from the original on 30 June 2024. Retrieved 11 July 2024.
  65. ↑ Daw Z, Padmore R, Neurath D, Cober N, Tokessy M, Desjardins D, et al. (August 2008). "Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis". Transfusion. 48 (8): 1598–1601. doi:10.1111/j.1537-2995.2008.01721.x. PMID 18466176. S2CID 6010463.
  66. ↑ Lassiter HA, Bibb KW, Bertolone SJ, Patel CC, Stroncek DF (February 1993). "Neonatal immune neutropenia following the administration of intravenous immune globulin". The American Journal of Pediatric Hematology/Oncology. 15 (1): 120–123. doi:10.1097/00043426-199302000-00019. PMID 8447553.
  67. ↑ Sugita K, Eguchi M (January 2005). "Suppressive effect of intravenous immunoglobulin on peripheral blood neutrophil count in patients with idiopathic thrombocytopenic purpura". Journal of Pediatric Hematology/Oncology. 27 (1): 7–10. doi:10.1097/01.mph.0000149239.68396.72. PMID 15654271.
  68. ↑ Stoevesandt J, Heitmann J, Goebeler M, Benoit S (December 2020). "[Not Available]". Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology. 18 (12): 1394–1404. doi:10.1111/ddg.14310_g. PMID 33373142.
  69. ↑ Lichtiger B (April 1994). "Laboratory Serologic Problems Associated with Administration of Intravenous IgG". Current Issues in Transfusion Medicine. 3. The University of Texas M. D. Anderson Cancer Center: 1–7. Archived from the original on 5 March 2016. Retrieved 23 November 2015.
  70. 1 2 3 4 5 6 7 8 9 Skoda-Smith S, Torgerson TR, Ochs HD (February 2010). "Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease". Therapeutics and Clinical Risk Management. 6: 1–10. doi:10.2147/tcrm.s4353. PMC 2817783. PMID 20169031.
  71. 1 2 3 Epland K, Suez D, Paris K (September 2022). "A clinician's guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases". Allergy, Asthma, and Clinical Immunology. 18 (1) 87. doi:10.1186/s13223-022-00726-7. PMC 9526304. PMID 36180928.
  72. ↑ Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, et al. (December 2009). "Subcutaneous immunoglobulin: opportunities and outlook". Clinical and Experimental Immunology. 158 (Suppl 1): 51–59. doi:10.1111/j.1365-2249.2009.04027.x. PMC 2801034. PMID 19883424.
  73. ↑ Powell L. "Re: A Message from CSL Behring to Current Vivaglobin Patients in the United States" (PDF). Primary Immune Foundation. Archived (PDF) from the original on 22 December 2015. Retrieved 24 November 2015.
  74. ↑ Lee Martin N, Butani Lavjay (2005). "Intravenous Immunoglobulin (IVIG) in Rheumatologic Diseases: A Review of its Mechanism of Action". Current Rheumatology Reviews. 1 (3): 289–293. doi:10.2174/157339705774612355.
  75. ↑ Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. (October 1998). "Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin". Science. 282 (5388): 490–493. Bibcode:1998Sci...282..490V. doi:10.1126/science.282.5388.490. PMID 9774279.
  76. 1 2 3 4 Maverakis E, Kim K, Shimoda M, Gershwin ME, Patel F, Wilken R, et al. (February 2015). "Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review". Journal of Autoimmunity. 57 (6): 1–13. doi:10.1016/j.jaut.2014.12.002. PMC 4340844. PMID 25578468.
  77. ↑ Gern JE (August 2002). "Antiinflammatory Activity of IVIG Mediated through the Inhibitory FC Receptor". Pediatrics. 110 (2): 467–468. doi:10.1542/peds.110.S2.467a. Archived from the original on 11 June 2008.
  78. ↑ Nimmerjahn F, Ravetch JV (January 2007). "The antiinflammatory activity of IgG: the intravenous IgG paradox". The Journal of Experimental Medicine. 204 (1): 11–15. doi:10.1084/jem.20061788. PMC 2118416. PMID 17227911.
  79. ↑ Galeotti C, Kaveri SV, Bayry J (December 2017). "IVIG-mediated effector functions in autoimmune and inflammatory diseases". International Immunology. 29 (11): 491–498. doi:10.1093/intimm/dxx039. PMID 28666326.
  80. ↑ Maddur MS, Kaveri SV, Bayry J (November 2017). "Circulating Normal IgG as Stimulator of Regulatory T Cells: Lessons from Intravenous Immunoglobulin" (PDF). Trends in Immunology. 38 (11): 789–792. doi:10.1016/j.it.2017.08.008. PMID 28916232. Archived (PDF) from the original on 1 February 2022. Retrieved 12 January 2022.
  81. ↑ Othy S, Topçu S, Saha C, Kothapalli P, Lacroix-Desmazes S, Käsermann F, et al. (July 2014). "Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin". European Journal of Immunology. 44 (7): 2059–2063. doi:10.1002/eji.201444440. PMID 24700174. S2CID 29700587.
  82. ↑ Campbell IK, Miescher S, Branch DR, Mott PJ, Lazarus AH, Han D, et al. (June 2014). "Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils". Journal of Immunology. 192 (11): 5031–5038. doi:10.4049/jimmunol.1301611. PMC 4025610. PMID 24760152.
  83. ↑ Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, et al. (January 2003). "Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin". Blood. 101 (2): 758–765. doi:10.1182/blood-2002-05-1447. PMID 12393386.
  84. ↑ Das M, Karnam A, Stephen-Victor E, Gilardin L, Bhatt B, Kumar Sharma V, et al. (January 2020). "Intravenous immunoglobulin mediates anti-inflammatory effects in peripheral blood mononuclear cells by inducing autophagy". Cell Death & Disease. 11 (1) 50. doi:10.1038/s41419-020-2249-y. PMC 6978335. PMID 31974400.
  85. ↑ Trinath J, Hegde P, Sharma M, Maddur MS, Rabin M, Vallat JM, et al. (August 2013). "Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells". Blood. 122 (8): 1419–1427. doi:10.1182/blood-2012-11-468264. PMID 23847198.
  86. ↑ Maddur MS, Vani J, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J (March 2011). "Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin". The Journal of Allergy and Clinical Immunology. 127 (3): 823–30.e1–7. doi:10.1016/j.jaci.2010.12.1102. PMID 21281961. S2CID 2323773.
  87. ↑ Galeotti C, Stephen-Victor E, Karnam A, Das M, Gilardin L, Maddur MS, et al. (August 2019). "Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE" (PDF). The Journal of Allergy and Clinical Immunology. 144 (2): 524–535.e8. doi:10.1016/j.jaci.2018.10.064. PMID 30529242. S2CID 54476352. Archived (PDF) from the original on 7 March 2020. Retrieved 8 July 2022.
  88. ↑ Galeotti C, Karnam A, Dimitrov JD, Chevailler A, Kaveri SV, Bayry J (April 2020). "Anti-IgE IgG autoantibodies isolated from therapeutic normal IgG intravenous immunoglobulin induce basophil activation". Cellular & Molecular Immunology. 17 (4): 426–429. doi:10.1038/s41423-019-0334-x. PMC 7109030. PMID 31797906.
  89. ↑ Clynes R (January 2005). "Immune complexes as therapy for autoimmunity". The Journal of Clinical Investigation. 115 (1): 25–27. doi:10.1172/JCI23994. PMC 539209. PMID 15630438.
  90. ↑ Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH (June 2006). "Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells". Nature Medicine. 12 (6): 688–692. doi:10.1038/nm1416. PMID 16715090. S2CID 40468774.
  91. ↑ Bayry J, Thirion M, Misra N, Thorenoor N, Delignat S, Lacroix-Desmazes S, et al. (October 2003). "Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases". Neurological Sciences. 24 (Suppl 4): S217–S221. doi:10.1007/s10072-003-0081-7. PMID 14598046. S2CID 5945755.
  92. ↑ Janke AD, Yong VW (April 2006). "Impact of IVIg on the interaction between activated T cells and microglia". Neurological Research. 28 (3): 270–274. doi:10.1179/016164106X98143. PMID 16687052. S2CID 18239570.
  93. ↑ Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. (January 2015). "The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis". The Journal of Infectious Diseases. 211 (1): 80–90. doi:10.1093/infdis/jiu396. PMC 4264590. PMID 25030060.
  94. ↑ "Antivenoms". www.who.int. Archived from the original on 7 May 2023. Retrieved 23 May 2023.
  95. ↑ Dias da Silva W, De Andrade SA, Megale ÂA, De Souza DA, Sant'Anna OA, Magnoli FC, et al. (September 2022). "Antibodies as Snakebite Antivenoms: Past and Future". Toxins. 14 (9): 606. doi:10.3390/toxins14090606. PMC 9503307. PMID 36136544.
  96. ↑ Ramasamy S, Liu CQ, Tran H, Gubala A, Gauci P, McAllister J, et al. (October 2010). "Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents". British Journal of Pharmacology. 161 (4): 721–748. doi:10.1111/j.1476-5381.2010.00939.x. PMC 2992890. PMID 20860656.
  97. ↑ Plotkin S, Orenstein WA, Offit PA (2012). Vaccines. Elsevier Health Sciences. pp. 103, 757. ISBN 978-1-4557-0090-5. Archived from the original on 9 January 2017.
  98. ↑ "Rho(D) Immune Globulin". Drugs.com. The American Society of Health-System Pharmacists. Archived from the original on 9 January 2017. Retrieved 8 January 2017.
  99. ↑ Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, Netesov SV (February 1999). "Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections". The Journal of Infectious Diseases. 179 (Suppl 1): S218–S223. doi:10.1086/514294. PMID 9988187.
  100. ↑ plasvacc (20 May 2021). "What is Hyperimmunized Plasma?". Plasvacc USA. Archived from the original on 27 March 2023. Retrieved 23 May 2023.
  101. ↑ "Eight Guiding Principles for Effective Use of IVIG for Patients with Primary Immunodeficiency" (PDF). American Association of Allergists and Immunologists. Archived (PDF) from the original on 5 March 2016. Retrieved 23 November 2015.
  102. ↑ Pierce LR (14 March 2018). Summary Basis for Regulatory Action – Hizentra (PDF) (Report). Review Office Signatory Authority Tejashri Purohit-Sheth. U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 20 March 2018. Retrieved 20 March 2018.
  103. ↑ Berman K. "SCIG: New Therapeutic Uses Beyond PI?" (PDF). IG Living (February–March 2015): 28–32. Archived (PDF) from the original on 27 October 2015. Retrieved 23 November 2015.
  104. 1 2 "An EU-wide overview of the market of blood, blood components and plasma derivatives focusing on their availability for patients Creative Ceutical Report, revised by the Commission to include stakeholders' comments" (PDF). Creative Ceutical & EU commission. Archived (PDF) from the original on 22 December 2015. Retrieved 7 December 2015.
  105. ↑ "transfusion.com.au". transfusion.com.au. Archived from the original on 4 September 2019. Retrieved 14 November 2019.
  106. ↑ Pollack A (17 July 2012). "Small Trial Hints Drug Can Slow Alzheimer's". The New York Times. Archived from the original on 19 July 2012. Retrieved 19 July 2012.
  107. ↑ "Experimental Alzheimer's drug Gammagard may stall memory decline, small study suggests". CBS News. 17 July 2012. Archived from the original on 19 July 2012. Retrieved 19 July 2012.
  108. ↑ "Another Alzheimer's Drug Fails Phase III Trial". Archived from the original on 7 June 2013.
  109. ↑ "FDA Approves Octapharma USA Investigational New Drug Application for Severe COVID-19 Patients". www.businesswire.com. 20 May 2020. Archived from the original on 21 June 2020. Retrieved 28 May 2020.
  110. ↑ Boyer LV, Theodorou AA, Berg RA, Mallie J, Chávez-Méndez A, García-Ubbelohde W, et al. (May 2009). "Antivenom for critically ill children with neurotoxicity from scorpion stings". The New England Journal of Medicine. 360 (20): 2090–2098. doi:10.1056/NEJMoa0808455. PMID 19439743.
  111. ↑ Williams DJ, Habib AG, Warrell DA (August 2018). "Clinical studies of the effectiveness and safety of antivenoms". Toxicon. 150: 1–10. Bibcode:2018Txcn..150....1W. doi:10.1016/j.toxicon.2018.05.001. PMID 29746978. S2CID 13665273.